Streetbeat News

Products Services

GTBIF

Ohio is nearing the launch of its recreational cannabis market, with 34 medical cannabis businesses approved to expand into adult-use sales. Key players like Riviera Creek, Pure Ohio Wellness, and Green Thumb Industries Inc (OTC:GTBIF) are ramping up production. However, sales are pending until dispensaries receive dual-use licenses by September 7. House Bill 230, introducing oral fluid tests for impaired drivers, has sparked controversy over its reliability.

Portfolio Pulse from Patricio Liddle

July 31, 2024 | 9:11 pm

CTNM

Contineum Therapeutics (NASDAQ:CTNM) announced the publication of preclinical data on PIPE-307, a selective M1 receptor inhibitor for relapse-remitting multiple sclerosis, in the Proceedings of the National Academy of Sciences. The data suggest PIPE-307 could be a first-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:07 pm

RYAN

Ryan Specialty has announced an exclusive relationship with MagMutual through Sapphire Blue to develop advanced solutions for complex healthcare risks. This initiative is part of Ryan Specialty Underwriting Managers.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:06 pm

XAIR

Beyond Air has announced the publication of a scientific article on the safety evaluation of high-dose inhaled nitric oxide in COVID-19 viral pneumonia in Scientific Reports, an online journal by Nature Publishers.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm

RCEL

AVITA Medical (NASDAQ: RCEL) has entered into an exclusive multi-year agreement with Regenity Biosciences for the marketing, sales, and distribution of a unique collagen-based dermal matrix, pending FDA 510(k) clearance.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:03 pm

SAVA

Cassava Sciences, Inc. (NASDAQ:SAVA) saw a significant stock price increase after announcing an extension of its open-label extension trials for its Alzheimer's treatment, simufilam. The extension aims to provide continuous treatment for patients and gather more long-term data. The company is also conducting two major Phase 3 studies, with results expected in 2024 and 2025.

Portfolio Pulse from Vaishali Prayag

July 31, 2024 | 9:01 pm

AVDL

Avadel Pharmaceuticals (NASDAQ: AVDL) has announced the dosing of the first patient in its Phase 3 REVITALYZ trial for LUMRYZ, an extended-release oral suspension aimed at treating idiopathic hypersomnia.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:00 pm

IMRX

Immuneering Corporation (NASDAQ:IMRX) has been granted FDA Fast Track designation for its lead program, IMM-1-104, as a first-line treatment for pancreatic ductal adenocarcinoma (PDAC). This follows a previous Fast Track designation for second-line treatment. The company expects initial data from its Phase 2a trial in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:59 pm

ENVX

Enovix shares surged after the company reported better-than-expected Q2 financial results and announced a non-binding MOU with a Global Automotive OEM to scale its cell architecture into the EV market.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:55 pm

NFG

National Fuel Gas (NFG) has issued preliminary fiscal 2025 earnings guidance of $5.75-$6.25 per share, compared to the $6.29 estimate. The company expects modest long-term production growth and reduced capital expenditures in its non-regulated segments, driven by higher natural gas prices. Regulated segments are projected to see revenue growth due to recent rate cases and continued investments in system modernization. Overall, NFG anticipates stable and predictable returns for shareholders.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:54 pm